OSTEOSYN™ CENTER
WELLNESS

Chondroitin Intervention Study for Joint Care and Support
February - June 2016

Preliminary Study Report

Summary of Preliminary Findings

The Study collected and measured wellness, activity, and joint pain and discomfort levels before and after intervention with chondroitin sulfate preparations in participants voluntarily enrolled and submitted assessment data. In pain assessment, 29% participants reported joint pain that "interferes with tasks" in baseline data, and after 30 or more days of chondroitin intervention, 11% participants reported pain at this level, reflecting a drop of about 18 percentage points and a clear improvement. Similarly in the wellness and activity measurements, participants reported broad-based shifts left to right in both assessment scales, by up to 25 percentage points, reflecting clear improvement in general sense of wellbeing and in increased level of activities.

% Participants reporting on joint pain scale, before and after:



% Participants reporting on wellness scale, before and after:



% Participants reporting activity scale, before and after:



Participants and Study Program

The subject study was designed to measure the effect of oral chondroitin preparations on volunteer participants with self-reported joint pain or discomfort with or without diagnosis of osteoarthritis. Participants include former sports players, members of adult day-care facilities, patients of an orthopedic practice in the VA hospital system, homemakers, and other participants. At the time of this preliminary report, a total of 76 participants had enrolled and submitted baseline health information.

Each participant was offered a free 30-day study sample of chondroitin capsules, including one formulation containing 1000mg of pharmaceutical grade chondroitin sulfate in either sodium or calcium form, and one formulation containing the same along with 1000mg of glucosamine hydrochloride. The study duration is designed to be between 4 to 12 weeks. Participants were advised to purchase additional capsules when necessary.

As of today, a total of 36 participants have sent in their follow up assessment data returns after finishing using the study sample capsules.

Baseline Data Sets:

Enrollment: 76

Age: Range - 51 to 92, Median age: 78, Average age: 76.8

Gender: Female 53.95%, Male 46.05%

Wellness scale:



Activity scale:



Activities:



Pain scale:



Joint issue locations:



Assessment Data Returns

Number Returned: 36

Capsule type:



Wellness scale:



Activity scale:



Activities:



Pain scale:



Joint issue locations:



General assessment (static):

Response rate -

Wellness data comparison:

	Wellness Scale	Baseline - 76 Participants	Assessment at 30-day Interval - 36 Participants
Percentage Participants Reporting %	1. Poor	22.4	2.8
	2. Need to improve	38.2	27.8
	3. Relatively well	26.3	36.1
	4. Well	10.5	30.6
	5. Vibrant	2.6	2.8

Activity data comparison:

	Activity Scale	Baseline - 76 Participants	Assessment at 30-day Interval - 36 Participants
Percentage Participants Reporting %	1. Not active	9.2	0
	2. Little activities	42.1	16.7
	3. Active	22.4	47.2
	4. Daily exercise	25	36.1
	5. Sports player	1.3	0

Pain and discomfort data comparison:

	Pain and Discomfort Scale	Baseline - 76 Participants	Assessment at 30-day Interval - 36 Participants
Percentage Participants Reporting %	0-No pain or discomfort	1.3	5.6
	1-Very mild	7.9	8.3
	2-Mild	7.9	25.0
	3-Tolerable	14.5	11.1
	4-Moderate	18.4	19.4
	5-Interferes with tasks	28.9	11.1
	6-Intense pain	11.8	13.9
	7-Interferes with concentration	3.9	2.8
	8-Severe pain	1.3	2.8
	9-Interferes with basic needs	1.3	0
	10-Worst pain/immobile	2.6	0

Adverse events:

One case of allergy attack likely associated with glucosamine hydrochloride content of Chondroitin-Glucosamine preparation administered - one female Participant reporting

Note on one adverse event report

One Participant Reported Allergic Reaction Likely Associated Glucosamine Hydrochloride Content of Chondroitin-Glucosamine 2000 Preparation

Event Report:

Participant: Female, 76 years of age
Location: A Plus Adult Day Care and Medical Center
Enrollment: June 1, 2016
Program: Open-Label Chondroitin Intervention Study on Joint Care and Support
Administrator: Synutra Pure, Ltd

Event summary:
Participant completed and submitted Enrollment Form with help of Administrator staff on June 1, 2016. In baseline data questionnaires, Participant described her general health condition as "need to improve", activity levels as "active" with walking as daily activity, and marked "5" in the pain scale that describes pain or discomfort that "interferes with tasks" in her knees and hands. In completing the enrollment process, Participant was asked to state if she had allergy concerns with crustacean shellfish (shrimp, crab, etc.) before receiving study sample capsules. With confirmation that Participant has had no concern over the listed class of possible allergen,

she was offered one unit of 30-serving Chondroitin-Glucosamine 2000 preparation that contains 1000mg of chondroitin sulfate sodium, along with 1000mg of glucosamine hydrochloride.

On June 14th, our staff received a call on our toll-free line from daughter of Participant. The daughter reported that Participant had started to take the Study sample capsules orally as instructed the previous evening. And about two hours after ingesting the capsules, Participant started to develop a skin rash, and later began to experience gastro-intestine reactions that caused vomiting through the evening and lasted until next day. Taking the report, Study administration staff advised that Participant should stop taking the capsules, seek medical help, and monitor and report further developments.

On June 15th, Study administrator representative followed up on Participant conditions and developments in telephone conversation with daughter of Participant during which it was confirmed that allergic reactions had subsided and Participant conditions returned to normal that day. It was also noted that Participant had had lighter but similar reactions previously to a glucosamine containing name-brand joint health preparation under the label of "Move Free." In these and ensuing discussions regarding this event, we are alarmed by the fact that the current allergen disclosure for preparations containing glucosamine as adhered to by the industry does not adequately warn of the possible adverse impact on people who do not exhibit allergic reactions to shellfish extracts.

In our preliminary assessment, more precise and clearer disclosure naming glucosamine as a possible allergen is needed.

As of the time of this report, there is no evidence or reason for us to believe the allergic reaction experienced by Participant may be associated with the Chondroitin sulfate sodium ingredient in the preparation.

Follow Up Actions:

In the wake of the event, we intend to stay engaged with the Participant's family to the extent necessary and stand ready to respond to any new developments plausibly associated with the event. We also intend to work closely with A Plus' nurse station to monitor any health issues that may arise from participation in the Study and stand ready to provide any assistance to the Center if needed. We are also prepared to make ourselves available to explain to Study Participants in greater detail about the Study and the capsules should they have any questions or concerns.